Revenues (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):

	Three months ended September 30,
	2019						2018
	US		ROW		Total		US		ROW		Total
Enbrel® (etanercept)	$	1,323	$	43	$	1,366	$	1,242	$	50	$	1,292
Neulasta® (pegfilgrastim)	619		92		711		897		154		1,051
Prolia® (denosumab)	425		205		630		354		178		532
XGEVA® (denosumab)	356		120		476		323		110		433
Aranesp® (darbepoetin alfa)	204		248		452		248		229		477
KYPROLIS® (carfilzomib)	163		103		266		142		90		232
EPOGEN® (epoetin alfa)	215		—		215		252		—		252
Sensipar®/Mimpara® (cinacalcet)	38		71		109		330		79		409
Other products	686		552		1,238		472		360		832
Total product sales(1)	$	4,029	$	1,434	5,463		$	4,260	$	1,250	5,510
Other revenues					274						394
Total revenues					$	5,737					$	5,904

	Nine months ended September 30,
	2019						2018
	US		ROW		Total		US		ROW		Total
ENBREL	$	3,744	$	136	$	3,880	$	3,544	$	155	$	3,699
Neulasta®	2,231		325		2,556		2,854		452		3,306
Prolia®	1,273		647		1,920		1,070		566		1,636
XGEVA®	1,091		355		1,446		994		336		1,330
Aranesp®	578		724		1,302		714		689		1,403
KYPROLIS®	483		295		778		430		287		717
EPOGEN®	657		—		657		746		—		746
Sensipar®/Mimpara®	216		228		444		1,069		257		1,326
Other products	1,889		1,451		3,340		1,353		1,016		2,369
Total product sales(1)	$	12,162	$	4,161	16,323		$	12,774	$	3,758	16,532
Other revenues					842						985
Total revenues					$	17,165					$	17,517

^____________ 

⁽¹⁾ 

Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2019 and 2018.